**Supplemental Figure S1**

**STROBE Statement—Checklist of items that should be included in reports of *cohort studies***

| Item No | Recommendation                                                                 | Yes/No/NA | Page/Line |
|---------|--------------------------------------------------------------------------------|-----------|-----------|
| **Title and abstract** | (a) Indicate the study’s design with a commonly used term in the title or the abstract | Yes       | Page 3    |
|         | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Yes       | Page 3    |
| **Introduction** |                                                                                   |           |           |
| 2       | Background/rationale Explain the scientific background and rationale for the investigation being reported | Yes       | Page 4    |
| **Objectives** | State specific objectives, including any prespecified hypotheses                       | Yes       | Page 5    |
| **Methods** |                                                                                   |           |           |
| 4       | Study design Present key elements of study design early in the paper                  | Yes       | Page 5    |
| 5       | Setting Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Yes       | Page 5    |
| 6       | Participants (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | Yes       | Page 10   |
|         | (b) For matched studies, give matching criteria and number of exposed and unexposed | Yes       | Page 6-8  |
| 7       | Variables Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Yes       | Page 8    |
| 8       | Data sources/measurement For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Yes       | Page 8    |
| 9       | Bias Describe any efforts to address potential sources of bias                                      | NA       |           |
| 10      | Study size Explain how the study size was arrived at                                            | Yes       | Page 10   |
| 11      | Quantitative variables Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Yes       | Page 7    |
| 12      | Statistical methods (a) Describe all statistical methods, including those used to control for confounding | Yes       | Page 9    |
|         | (b) Describe any methods used to examine subgroups and interactions                               | NA       |           |
|         | (c) Explain how missing data were addressed                                                                 | Yes       | Page 10   |
|         | (d) If applicable, explain how loss to follow-up was addressed                                         | NA       |           |
|         | (e) Describe any sensitivity analyses                                                                  | Yes       | Page 10   |
| **Results** |                                                                                   |           |           |
| 13      | Participants (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for | Yes       | Page 10   |
eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
(b) Give reasons for non-participation at each stage
Yes Page 10
(c) Consider use of a flow diagram
Yes Appendix Figure 1

| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Yes Page 10 |
|------------------|-----|--------------------------------------------------------------------------------------------------------------------------------|-------------|
|                   |     | (b) Indicate number of participants with missing data for each variable of interest                                                                 | NA          |
|                   |     | (c) Summarise follow-up time (eg, average and total amount)                                                                                                                                  | Yes Page 10 |

| Outcome data     | 15* | Report numbers of outcome events or summary measures over time                                                                                                                               | Yes Page 11 |

| Main results     | 16  | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Yes Page 12 |
|------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
|                   |     | (b) Report category boundaries when continuous variables were categorized                                                                                                                  | Yes Appendix Table 1 |
|                   |     | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period                                                                          | Yes Page 11 |

| Other analyses   | 17  | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses                                                                                               | Yes Appendix Table 4, 5 |

| Discussion       |     | Summarise key results with reference to study objectives                                                                                                                                | Yes Page 12 |
|------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| Limitations      | 19  | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias                                         | Yes Page 14 |
| Interpretation   | 20  | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                          | Yes Page 12 |
| Generalisability | 21  | Discuss the generalisability (external validity) of the study results                                                                                                                    | Yes Page 13 |

| Other information|     | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based                                      | Yes Page 15 |

*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.